Resource impact statement
Cancer Drugs Fund technology
NICE has recommended abemaciclib with fulvestrant for use within the Cancer Drugs Fund for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in people who have had endocrine therapy only if exemestane plus everolimus would be the most appropriate alternative.
Abemaciclib with fulvestrant will be available to the NHS in line with the managed access agreement with NHS England. As part of this, NHS England and Eli Lilly have a commercial access agreement that makes abemaciclib available to the NHS at a reduced cost. The financial terms of the agreement are commercial in confidence.
The resource impact of abemaciclib with fulvestrant will be covered by the Cancer Drugs Fund budget. The guidance will be reviewed by the date the managed access agreement expires (December 2021) or when the results of the managed access agreement data collection are available, whichever is sooner. The aim of the review is to decide whether the drug can be recommended for routine use. Further information can be found in NHS England’s Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund) - A new deal for patients, taxpayers and industry.
It is estimated that up to 3,300 people per year with hormone receptor-positive, HER2-negative advanced breast cancer after treatment with endocrine therapy are eligible for treatment with abemaciclib with fulvestrant.
This technology is commissioned by NHS England. Providers are NHS hospital trusts.
This page was last updated: